Trial · NCT06718686
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in stool and serum short-chain fatty acid levels | 10 weeks | Change in SCFA in stool and serum in rifaximin SSD phase vs placebo phase |
| Primary | Change in bile acids in stool and serum | 10 weeks | Change in bile acids in stool and serum in rifaximin SSD phase vs placebo phase |
| Secondary | Systemic inflammatory change | 10 weeks | serum lipopolysaccharide-binding protein (LBP), inflammatory cytokines (IL-6, TNF-α, IL-10, IL-1β) in placebo phase vs Rifaximin SSD phase |
| Secondary | Stool microbiome composition | 10 weeks | 16SrRNA microbiome composition and diversity change in placebo vs Rifaximin SSD phase |
| Secondary | Change in dementia biomarkers | 10 weeks | Plasma concentrations of Aβ42 and Aβ40 to calculate amyloid-β (Aβ)42/40 ratio and plasma concentration of phospho-tau (p-tau)181 in placebo vs Rifaximin SSD phase |
| Secondary | MMSE | 10 weeks | Change in MMSE between the 2 phases |
| Secondary | Cognitive testing using Psychometric Hepatic Encephalopathy Score | 10 weeks | Change in PHES in placebo vs rifaximin SSD phase |
| Secondary | Clinical Dementia Rating - Sum of Boxes (CDR-SB) | 10 weeks | Change in CDR-SB in placebo vs Rifaximin SSD phase |
| Secondary | EncephalApp Stroop performance | 10 weeks | Change in off time and on time in seconds between placebo and rifaximin SSD phases |
| Secondary | Critical flicker fusion analysis | 10 weeks | change in threshold to see CFF fusion in rifaximin SSD vs placebo phases |
| Secondary | Katz Index of Independence in Activity of Daily Living (ADL) | 10 weeks | change in the score above judged by caregivers in placebo vs Rifaximin SSD phase |
| Secondary | Lawton-Brody Instrumental Activities of Daily Living (IADL) | 10 weeks | Change in instrument score above by caregivers in rifaximin SSD vs placebo phase |
| Secondary | Zarit Burden Interview short form | 10 weeks | Change in instrument score above by caregivers in rifaximin SSD vs placebo phase |
| Secondary | Sickness Impact profile | 10 weeks | change in score of the QOL instrument above in placebo vs rifaximin SSD phases |
| Secondary | PROMIS-29 | 10 weeks | change in score of the QOL instrument above in placebo vs rifaximin SSD phases |
| Secondary | Safety | 10 weeks | Serious adverse event rates in placebo versus rifaximin SSD phases |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06718686/registered